Background-A functional polymorphism in the inhibitory IgG-Fc receptor gene Fc␥RIIB influences intravenous immunoglobulin (IVIG) response in Kawasaki disease (KD), a vasculitis preferentially affecting the coronary arteries in children. We tested the hypothesis that the polymorphisms in the activating receptors (Fc␥RIIA, Fc␥RIIIA, and Fc␥RIIIB) also influence susceptibility, IVIG treatment response, and coronary artery disease in patients with KD. Methods and Results-We genotyped polymorphisms in the activating Fc␥RIIA, Fc␥RIIIA, and Fc␥RIIIB using pyrosequencing in 443 patients with KD, including 266 trios and 150 single parent-child pairs, in northwest United States and genetically determined race with 155 ancestry informative markers. We used family-based association to test for transmission disequilibrium and further generated pseudosibling controls for comparisons with the cases. The Fc␥RIIA-131H variant showed an association with KD (Pϭ0.001) with an additive odds ratio (OR) of 1.51 (95% CI, 1.16 -1.96; Pϭ0.002) for the primary combined population, which persisted in both white (Pϭ0.04) and Asian (Pϭ0.01) subgroups and is consistent with the recent genome-wide association study. We also identified overtransmission of the Fc␥RIIIB neutrophil antigen 1 (NA1) variant among IVIG nonresponders (Pϭ0.0002) and specifically to white IVIG nonresponders (Pϭ0.007). ORs for overall and white nonresponders were 3.67 (95% CI, 1.75-7.66; Pϭ0.0006) and 3.60 (95% CI, 1.34 -9.70; Pϭ0.01), respectively. Excess NA1 transmission also occurred in patients with KD with coronary artery disease (OR additive , 2.13; 95% CI, 1.11-4.0; Pϭ0.02).
identification of candidate genes involved in Kawasaki disease pathogenesis and polymorphisms that can predict treatment response. IgG-Fc region receptors (FC␥Rs) represent plausible Kawasaki disease mediators because of their direct interaction with IgG. Fc␥Rs are a heterogeneous group of hematopoietic cell surface glycoproteins that are expressed primarily on human effector cells of the immune system, particularly macrophages, monocytes, myeloid cells, and dendritic cells. 10 These molecules facilitate antibody-antigen interactions. Studies in mice lacking various forms of Fc␥R have documented their key roles in the balance between activating and inhibitory receptor signals in experimental idiopathic thrombocytopenic purpura as well as for how modulation of this balance might account for the therapeutic effects of IVIG. 11 Although the disease processes in mice and humans are not precisely the same, the mechanisms of action of IVIG in these murine models have important connections with their human analogs. The murine models suggest an important and possibly dominant role for the inhibitory Fc␥RIIB in the IVIG antiinflammatory mechanism. Genetic association studies in humans support such Fc␥RIIB participation. However, the low frequency of the particular functional Fc␥RIIB polymorphisms in all populations limits its clinically relevant role. 12 The activating Fc␥Rs interact with the single inhibitory receptor Fc␥RIIB. Thus, we hypothesized that polymorphisms in the activating receptors (Fc␥RIIA, Fc␥RIIIA, and Fc␥RIIIB) influence the IVIG treatment response defined by clinical parameters. We also analyzed these receptors with regard to susceptibility and persistence of coronary artery disease (CAD) in patients with Kawasaki disease. We examined the influence of functional single-nucleotide polymorphisms (SNPs) in these genes using a family-based genetic study. We performed the study in a heterogeneous US-based population of patients with Kawasaki disease and their parents comprising some ethnic and racial admixture. Substantial Fc␥R allelic and locus heterogeneity has been demonstrated across different ethnic and racial groups; therefore, we also performed subgroup analyses in populations of European and Asian descent.
Methods

Study Population
Patients, their parents, and available siblings were identified through clinical databases and enrolled at the following participating centers: Seattle Children's Hospital, Oakland Children's Hospital, and Primary Children's Hospital of Utah. Retrospective cross-referencing of the hospital database and the heart center echocardiography databases confirmed the diagnosis and treatment of all participating patients with Kawasaki disease. After approval by the Institutional Review Board at all participating institutions, parents were approached for study recruitment, and informed consent was obtained.
Clinical Diagnosis of Kawasaki Disease
The definition of complete Kawasaki disease followed the standard epidemiological criteria recommended by the American Heart Association and American Academy of Pediatrics. Patients were also included if they had at least 2 clinical criteria and coronary artery involvement as defined in the American Heart Association guidelines. 5
Treatment Response
Treatment response was determined in patients receiving IVIG (2 g/kg) within 11 days of initial fever. 5 As stated in the American Heart Association/American Academy of Pediatrics-endorsed clinical report, 13 failure to respond to IVIG treatment was defined as either persistent fever (temperature Ͼ38°C) at Ͼ36 hours or recurrent fever at Ͼ36 hours after completion of the initial IVIG infusion. Patients receiving second doses of IVIG at Ͻ36 hours were excluded from treatment response analyses unless they had persistent fever despite a second dose of IVIG.
Coronary Artery Disease
CAD was defined by echocardiography as dilation (Z score Ͼ2.5 according to Boston Z score data 14 or aneurysm defined by Japanese Ministry of Health criteria persisting Ͼ6 weeks after IVIG treatment [2 g/kg]).
Biospecimen Collection and DNA Extraction
Most parents consented to have blood samples taken from their offspring with Kawasaki disease, and whole blood was collected in ACD (acid citrate dextrose) anticoagulant tubes. For the remainder, saliva was collected in Oragene kits (DNA Genotek) by a noninvasive technique proven to preserve DNA. Briefly, participants first rinsed their mouths with water to clear food particles and then expectorated 2 mL of saliva into the Oragene vial. Genomic DNA was extracted using the Versagene DNA purification kit (Gentra Systems) and quantified using the PicoGreen assay for doublestranded DNA, adjusted to a final concentration of 100 ng/L, and stored at Ϫ80°C in Tris-EDTA.
Activating Fc␥R Genes and Polymorphisms
The activating Fc␥RIIA, Fc␥RIIIA, and Fc␥RIIIB genes are all located at chromosome arm 1q23 11, 15 within a span of Ϸ200 kb. Fc␥RIIA has affinity for IgG and interacts with IgG or immunecomplexed IgG on cell surfaces. Fc␥RIIIB is a relatively low affinity receptor. Fc␥RIIIA is expressed as a membrane-spanning receptor on macrophages and natural killer cells. These 3 genes produce integral transmembrane glycoproteins that are considered functionally activating receptors.
Five well-characterized and functionally relevant SNPs were examined: (1) a common Fc␥RIIA SNP (rs1801274) affecting amino acid position 131 in extracellular domain 2 (Fc␥RIIA-131H/R), with A and G alleles at position 131 coding for codominantly expressed arginine (R) and histidine (H), respectively, and known to affect affinity for IgG2 and are associated with several immune-related diseases 10, 16, 17 ; (2) a common Fc␥RIIIA SNP (rs396991) affecting amino acid position 158 in extracellular domain 2 (Fc␥RIIIA-158V/ F), with G and T alleles coding either valine (V) or phenylalanine (F), respectively, and known to be associated with immune-related diseases 16 -18 where the valine isoform has a higher affinity for IgG1 and IgG3 than the phenylalanine isoform; (3) another triallelic Fc␥RIIIA SNP (rs10127939) at amino acid position 48 (Fc␥RIIIA-48L/R/H), with T, G, and A alleles encoding for either leucine (L), arginine (R), or histidine (H), respectively, and known to influence the binding of IgG by natural killer cells 19 ; and (4) 2 Fc␥RIIIB SNPs at positions 141 (rs403016) and 147 (rs447536) in the extracellular domain 1 that result in variable amino acid sequences resulting in 2 allotypic forms named neutrophil antigen 1 (NA1) and neutrophil antigen 2 (NA2). Although SNP 141 and SNP 147 are in a perfect linkage disequilibrium, haplotype is a conventional way to determine NA1 and NA2 allotypes, which has been well established in the literature. 20
Genotyping Methods
The functional polymorphisms in the Fc␥R family were genotyped by pyrosequencing methodology using a nested polymerase chain reaction (PCR) approach to ensure gene-specific amplification. 20 Initial gene-specific PCR amplifications of the DNA fragments around the SNP sites were followed by second-round-nested PCRs, using 0.25 L of the first-round PCR products as templates. All PCRs were carried out with Taq polymerase (Invitrogen). Biotinylated second-round PCR products amplified with primer pairs (1 of the primer pairs is labeled with biotin) were used for subsequent pyrosequencing reactions. The PCRs and cycling conditions have been previously described. 20, 21 Briefly, amplification is performed with 1 biotinylated primer to allow for purification of a singlestranded template for the pyrosequencing reaction. Following denaturation of the PCR amplicon in 0.1 mol/L NaOH for 10 minutes, the single-stranded product is immobilized to streptavidin-sepharose (Amersham Biosciences), washed, and annealed with 15 pmol of a pyrosequencing primer. The primers and probes for the 2 rounds of PCR and pyrosequencing primers are listed in the online-only Data Supplement Table. Pyrosequencing was performed according to the manufacturer's instructions as previously described. 22
Statistical Methods
First, genotype completeness was checked for each SNP, and Hardy-Weinberg equilibrium was examined in each ethnic group. Statistical analysis for Kawasaki disease susceptibility was performed by the transmission disequilibrium test, which tests for disequilibrium of transmission of alleles from heterozygous parents to affected child and, thus, applies to parent-child trios. The test statistic for the transmission disequilibrium test is distributed as a 2 with 1 degree of freedom and is calculated as (bϪc) 2 /(bϩc) where b and c are the number of transmissions and nontransmissions, respectively, of the allele from heterozygous parents to their affected children. All analyses were performed assuming additive genetic models with a minimum informative family size set to 10. We used the family-based association test (FBAT) to allow for larger families than trios and incomplete trios with or without siblings. Singlemarker FBAT analysis was used to estimate the single locus frequencies. 13 A significant P value (Ͻ0.05) and a positive Z statistic indicated that the allele at a specific locus is more frequently transmitted to patients with Kawasaki disease than is expected under the null hypothesis of no linkage and no association, whereas a significant P value and a negative Z statistic indicated a protective marker allele for Kawasaki disease. For those loci that showed significant differences in FBAT analysis, case/pseudosibling control analysis was performed as previously described. 23 The pseudosibling controls were generated from the 3 untransmitted parental genotypes, and conditional logistic regression was used to estimate odds ratios (ORs) and 95% CIs in the additive model.
As primary analysis of the study, FBAT analyses were performed separately for responders and nonresponders to determine whether alleles were differentially transmitted. Additionally, as a secondary analysis, differential transmission was examined among patients with and without CAD. All analyses were performed for the entire set of patients with Kawasaki disease and separately for whites and Asians as determined by the principal component analysis of ancestry informative markers (AIMs), as previously described. 12 Although FBAT accounts for population admixture, the underlying assumption of the same genetic association may not hold because of allelic and genetic heterogeneity in different ethnic groups. For ethnicity-specific analyses, only families with all members clustered in the same ethnic group (all 3 for trios and 2 for the parent-child pair) were included. For quality control, Mendelian inconsistency checks were performed with the AIMs, and both parents whose data contained genotyping errors in Ͼ1 SNP were excluded from the study.
Results
The genotype frequencies for all polymorphisms met Hardy-Weinberg expectations in each population (European and Asian ancestry), and the genotype data were complete for Ͼ95% of the individuals with samples available as the genotype was redone, if they failed in the first attempt. Based on the AIMs, the first 3 principal component values were used to discriminate individuals into 4 major race/ethnic groups (Figure) : (1) a homogenous European ancestry (white), (2) a more heterogeneous Asian ancestry, (3) a heterogeneous Hispanic ancestry (predominantly Mexican or Mexican American), and (4) a small group for African ancestry (black). However, there were many genetically heterogeneous individuals who could not be defined into 1 single race/ethnic group. Self-report (or as reported by parents) of all patients with Kawasaki disease and participating family members showed a slightly Ͻ90% match with the genetically determined ancestry: 570 of 599 who selfreported to be white matched, 153 of 173 who self-reported to be Asians matched, 147 of 166 who self-reported Hispanic matched, 95 self-reported multiple ethnicity, and 61 did not report any ethnicity. Based on the AIMs, the study was underpowered with a smaller sample size for blacks and Hispanics, although distinct from other race/ethnic groups as previously reported, 24 was very heterogeneous. Therefore, we restricted the analysis to European and Asian ancestry.
Other baseline demographic characteristics are shown in Table 1 . The median age of the probands at diagnosis was 34 months (interquartile range, 15-58 months), and 62% of them were boys, with a male-to-female ratio of 1.6:1, which is similar to the ratios reported in general populations. The median age between treatment responders (35 months; interquartile range, 16 -58 months) and nonresponders (31 months; interquartile range, 15-66 months) was not significantly different, and there were slightly more nonresponders (63%) than responders (60%) among boys. Of the 443 patients with Kawasaki disease recruited into the study (242 whites, 82 Asians, 88 Hispanics, and 31 blacks), 266 trios (156, 44, 52, and 14, respectively) and 150 single parent-child pair (75, 29, 30, and 16, respectively) were included in the transmission disequilibrium test analyses. Seven families were excluded because of Mendelian errors with AIMs. From the review of medical records, 267 patients (141 whites, 57 Asians, 51 Hispanics, and 18 of other ethnic groups) could be classified as IVIG treatment responsive and 86 (51 whites, 9 Asians, and 20 Hispanics, and 6 of other ethnic groups) as nonresponsive, with genetic data available for at least 1 biological parent participating in the study. Interestingly, Fc␥RIIIA-48 was triallelic mostly in whites but was Ͻ5% frequency in other ethnic groups.
Susceptibility
We tested the primary hypothesis relating to IVIG treatment response in patients of European (white) and Asian ancestry. However, these polymorphisms influence susceptibility for other inflammatory diseases. Accordingly, we first analyzed their association with disease within the entire study population. Most importantly, we showed excess A allele (histidine) transmission in Fc␥RIIA-131H/R from heterozygous parents to affected offspring (nϭ182, zϭϩ3.12, Pϭ0.001) in the additive model ( (Table 2) showed that statistical significance persisted in the combined responders; however, it seemed that the effect was largely observed in Asian responders. Further, using the pseudosibling controls (Table 3) , the A allele showed increased risk overall among IVIG responders (OR additive, 1.40; 95% CI, 1.01-1.95; Pϭ0.04). Relatively high risk occurred for this allele among Asian responders (OR additive , 4.00; 95% CI, 1.34 -11.96; Pϭ0.01).
The Fc␥RIIIA-158 G allele was transmitted less in Asians (nϭ29, zϭϪ2.00, Pϭ0.05) ( Table 2) , including mostly IVIG responders (nϭ19, zϭϪ2.04, Pϭ0.04) (Table 3 ). However, FCGRIIIA-48L/R/H occurring at low frequency showed no effects. Similarly, Fc␥RIIIB-NA1 showed no significant association with Kawasaki disease susceptibility (nϭ157, zϭϩ1.88, Pϭ0.06) ( Table 2 ).
IVIG Nonresponse
We found excessive transmission of Fc␥RIIIB-NA1 in the IVIG nonresponding subgroup (nϭ34, zϭϩ3.70, Pϭ0.0002) ( Table 3 ). This highly significant effect was detected in whites (nϭ20, zϭϩ2.71, Pϭ0.007) ( in the combined study population could be due to the nonresponders.
Coronary Artery Disease
As noted, prevention or resolution of CAD is the principal goal of Kawasaki disease therapy. Thus, we defined CAD persistence a priori as an important clinical parameter also related to IVIG response. We identified 86 patients with persistent CAD (42 whites, 18 Asians, and 26 of other ethnic groups), 331 with no CAD, and 26 with a missing diagnosis. Excess transmission of the A allele in Fc␥RIIA-131H/R occurred in patients with CAD (Table 4 ) but was not apparent in whites or Asians separately. However, this occurred in concert with excess transmission for the entire Kawasaki disease population. In contrast, Fc␥RIIIB-NA1 excess transmission occurred in patients with CAD, consistent with findings in the IVIG nonresponders, but despite a lack of apparent effect on the entire combined patients with Kawasaki disease.
Discussion
The principal finding in our hypothesis-driven study is that a highly significant association between IVIG response and Fc␥RIIIB genotype in patients with Kawasaki disease has important pharmacogenomic and clinical implications. Rein-forcing the demonstration that parental transmission of NA1 genotype substantially decreases the odds of appropriate clinical IVIG response, the study also showed that this genotype confers substantially greater risk of persistent CAD. To our knowledge, no prior investigation has specifically evaluated the impact of polymorphisms for genes transcribing Fc␥Rs on clinically defined IVIG response. However, few studies analyzed associations between Fc␥Rs, including NA1/NA2 and coronary artery lesions. 25, 26 Although they did not define coronary artery phenotype, only Biezeveld et al 25 reported slightly decreased risk (OR, 0.42; 95% CI, 0.16 -1.06; Pϭ0.06) of coronary artery lesions in white patients with Kawasaki disease with the genotype NA1/NA2 compared with NA1/NA1. Likely, the present study's greater number of informative patients combined with parent data, with genetically determined homogenous populations, within the transmission disequilibrium test and FBAT framework provided adequate power to detect these NA1 associations with clearly defined phenotypes. The potential biological mechanisms responsible for different IVIG responses between the NA1 and NA2 isoforms require elucidation. Fc␥RIIIB is expressed almost exclusively on neutrophils, although recent data show low-level expression in human basophils. 27 NA1 confers greater neutrophil IgG-dependent phagocytic capacity than NA2. 10 This may relate to differences in the number of functionally relevant N-linked glycosylation sites that affect their interaction with IgG because NA1 has a higher binding affinity for IgG1 and IgG3. Alternatively, NA1 and NA2 may interact differently with other cell surface receptors, such as ␤2 integrin, CD11b, and CD18. Some clinical and pathological evidence suggests an important role for neutrophils in Kawasaki disease and coronary artery pathogenesis. 28 In particular, CD11b expression on neutrophils rises during the acute disease phase, declines after treatment, and remains elevated in patients with persistent CAD. 29 The present data offer an intriguing possibility that IVIG manipulates NA1/NA2-dependent activity in Kawasaki disease.
We also found excess transmission of the more potent Fc␥RIIA-131H variant among patients with Kawasaki disease. This finding validates a recent report from a genomewide association study by an international Kawasaki disease consortium. 30 The polymorphism (A/g) in Fc␥RIIA-131H/R alters recognition of the ligand in that the receptor encoded by Fc␥RIIA-131H (A allele) shows greater binding affinity for IgG2 31 and, thus, more effective phagocytosis of IgG2opsonized particles. This receptor variant also shows decreased binding affinity for C-reactive protein, which shares several functional activities with IgG2 and is markedly elevated during acute Kawasaki disease. Tanuichi et al 26 previously reported an Fc␥RIIA-131H association with CAD in a small set of Japanese patients with Kawasaki disease. However, the present data suggest that this allele relates to overall Kawasaki disease susceptibility rather than to specific CAD risk.
The multiple Fc␥Rs interact with Fc␥RIIB (inhibitory), with one another, or both through their coligation at the immune effector cell membrane. Thus, functional polymorphisms within the genes regulating these receptors can alter the balance between activation and inhibition and thereby influence their interaction. Strengths of associations between individual Fc␥R SNPs and inflammatory disease susceptibility clearly vary by race and may be explained by the racial variation in the gene sequences of the other receptors. As previously noted, Fc␥RIIB polymorphisms influence IVIG response in patients with Kawasaki disease in a racially dependent manner. The presence of Fc␥RIIB (-120 A and -386 C) minor alleles in white patients improved their chance for positive IVIG therapeutic response. 12 Functionality for these SNPs within the human Fc␥RIIB promoter region has been confirmed in that they enhance transcription factor binding. Yet, these SNPs were absent in the Asians studied, further emphasizing that balance between the activating and inhibitory receptors varies by ethnicity. Although these Fc␥Rs are located in the same region, with high linkage disequilibrium, the SNPs were not highly correlated. The correlations, however, also varied between the 2 ethnic groups.
In following, we logically performed ethnicity-specific analyses for the Fc␥Rs in the current study. There are limitations related to the ethnic stratification. The low number of informative families for the SNPs within these subgroups limited the power of the observations. Correction for multiple testing is conventionally performed for noncandidate-based studies, such as genome-wide association studies, which evaluate numerous variants. Some might suggest that our stratification introduces the requirement for such correction. However, the need for correction in a hypothesis-driven study evaluating functional SNPs remains controversial. With regard to the observed associations related to the ethnic stratification as well as to CAD, significance is somewhat less. We cautiously report these latter findings, which will require validation with larger subject numbers in these ethnic groups.
